The expanding frontier of molecular neuropsychiatry is witnessing a profound shift away from synthetic, single-molecule pharmaceuticals toward full-spectrum botanical matrices. For decades, standard psychiatric models attempted to manage neurological imbalances, chemical dependencies, and emotional trauma by artificially suppressing specific neurotransmitters. However, contemporary clinical data indicates that these isolated interventions frequently result in receptor down-regulation, physical […]